Research programme: obesity therapy - Devgen
Latest Information Update: 09 Dec 2008
At a glance
- Originator Devgen
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 05 Nov 2008 Discontinued - Preclinical for Obesity in Belgium (unspecified route)
- 26 Feb 2007 Preclinical trials in Obesity in Belgium (unspecified route)